|
|
|
|
|
Sponsored by: |
Instituto de Olhos de Goiania |
Information provided by: | Instituto de Olhos de Goiania |
ClinicalTrials.gov Identifier: | NCT00556348 |
To report the short term anatomic and visual acuity response after intravitreal injection of bevacizumab (Avastin, Roche, Rio de Janeiro, Brazil) in patients with choroidal neovascularization secondary to age-related macular degeneration.
Condition | Intervention | Phase |
Age Related Macular Degeneration |
Drug: bevacizumab |
Phase IV |
Genetics Home Reference related topics: | X-linked juvenile retinoschisis |
MedlinePlus related topics: | Macular Degeneration |
ChemIDplus related topics: | Bevacizumab |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Intravitreal Bevacizumab for Choridal Neovascularization Secondary to Age-Related Macular Degeneration |
Estimated Enrollment: | 500 |
Study Start Date: | November 2005 |
Study Completion Date: | November 2007 |
Arms | Assigned Interventions |
1: Experimental |
Drug: bevacizumab
1.25mg
|
We conducted a retrospective study of 500 eyes with choroidal neovascularization secondary to age-related macular degeneration who were treated with at least two (initial and one month after) intravitreal injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months. Patients underwent Snellen visual acuity testing, optical coherence tomography (OCT) imaging and ophthalmoscopic examination at baseline and follow-up visits.
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | JN-02-2007-ARVO |
First Received: | November 9, 2007 |
Last Updated: | November 9, 2007 |
ClinicalTrials.gov Identifier: | NCT00556348 |
Health Authority: | Brazil: National Health Surveillance Agency |
|
|
|
|
|
|